Results 41 to 50 of about 70,621 (279)
A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer
Case Reports in Ophthalmology, 2022 Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old ...
Deborah Peeters +3 more
doaj +1 more source
Retracted: Trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in gastric cancer
FEBS Open Bio, 2018 Gastric cancer (GC) is one of the most prevalent cancers worldwide. Trastuzumab has been approved for the treatment of metastatic GC, gastroesophageal junction cancer, and breast cancer.
Linghe Luo, Haiyan Liu, Qian Xi
doaj +1 more source
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
Journal of Ovarian Research, 2010 Background Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and
Wilken Jason A +2 more
doaj +1 more source
Frontiers in Oncology, 2022 Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer.
Zhen-hao Wang +12 more
doaj +1 more source
Molecular Imaging, 2014 Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be ...
Sietske B.M. Gaykema +8 more
doaj +1 more source
Cell Death and Disease, 2021 Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive.
Jing Guo +8 more
doaj +1 more source
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Molecular Cancer, 2022 Background Approximate 25% HER2-positive (HER2+) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear.
Yun Ling +17 more
doaj +1 more source
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
Molecular Oncology, EarlyView.Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni +11 more
wiley +1 more source
Biomedicines, 2022 Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment.
Dmitrii Kamashev +7 more
doaj +1 more source
FEBS Open Bio, EarlyView.Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu +5 more
wiley +1 more source